Year 2019, Volume 5, Issue 3, Pages 569 - 571 2019-05-04

Rivaroxaban-induced acute pancreatitis

Özgür Sirkeci [1] , Emel Erkuş Sirkeci [2] , Belma Taşel [3]

25 266

Rivaroxaban is a direct factor Xa inhibitor and has been safely used since 2008. It is used for the detection of atrial fibrillation and venous thromboembolism. Pancreatitis is one of the rare but dangerous side effects of rivaroxaban. The case of a 53-year-old female patient that developed in the third month of drug usage was evaluated, and it was confirmed after a full analysis was conducted that excluded all other factors, such as biliary calculus, alcohol usage, hypertriglyceridemia, biochemical parameters, ultrasonography and computed tomography that the patient’s condition was caused by the use of Rivaroxaban. The aim of this case presentation is to indicate that awareness should be increased regarding the risks of using the drug Rivaroxaban, as it could lead to drug-induced pancreatitis, even though this is rare. 

drug-induced pancreatitis, rivaroxaban, drug safety
  • [1] Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008;92:889-923.
  • [2] Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis:an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61.
  • [3] http://www.ehealthme.com/ds/xarelto/pancreatitis/
  • [4] Tenner S. Drug induced acute pancreatitis: Does it exist? World J Gastroenterol 2014;20:16529-34.
  • [5] Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol 2014;5:405-15.
Primary Language en
Subjects Health Care Sciences and Services
Journal Section Case Reports
Authors

Orcid: 0000-0001-9048-5096
Author: Özgür Sirkeci (Primary Author)
Institution: Department of Internal Medicine, Near East University School of Medicine, Nicosia, Cyprus
Country: Cyprus


Orcid: 0000-0003-2743-7619
Author: Emel Erkuş Sirkeci
Institution: Department of Emergency Medicine, Near East University School of Medicine, Nicosia, Cyprus
Country: Cyprus


Orcid: 0000-0003-1515-6801
Author: Belma Taşel
Institution: Department of Cardiology, Near East University School of Medicine, Nicosia, Cyprus
Country: Cyprus


Bibtex @case report { eurj417972, journal = {The European Research Journal}, issn = {}, eissn = {2149-3189}, address = {The Association of Health Research and Strategy}, year = {2019}, volume = {5}, pages = {569 - 571}, doi = {10.18621/eurj.417972}, title = {Rivaroxaban-induced acute pancreatitis}, key = {cite}, author = {Sirkeci, Özgür and Erkuş Sirkeci, Emel and Taşel, Belma} }
APA Sirkeci, Ö , Erkuş Sirkeci, E , Taşel, B . (2019). Rivaroxaban-induced acute pancreatitis. The European Research Journal, 5 (3), 569-571. DOI: 10.18621/eurj.417972
MLA Sirkeci, Ö , Erkuş Sirkeci, E , Taşel, B . "Rivaroxaban-induced acute pancreatitis". The European Research Journal 5 (2019): 569-571 <http://dergipark.gov.tr/eurj/issue/42399/417972>
Chicago Sirkeci, Ö , Erkuş Sirkeci, E , Taşel, B . "Rivaroxaban-induced acute pancreatitis". The European Research Journal 5 (2019): 569-571
RIS TY - JOUR T1 - Rivaroxaban-induced acute pancreatitis AU - Özgür Sirkeci , Emel Erkuş Sirkeci , Belma Taşel Y1 - 2019 PY - 2019 N1 - doi: 10.18621/eurj.417972 DO - 10.18621/eurj.417972 T2 - The European Research Journal JF - Journal JO - JOR SP - 569 EP - 571 VL - 5 IS - 3 SN - -2149-3189 M3 - doi: 10.18621/eurj.417972 UR - https://doi.org/10.18621/eurj.417972 Y2 - 2018 ER -
EndNote %0 The European Research Journal Rivaroxaban-induced acute pancreatitis %A Özgür Sirkeci , Emel Erkuş Sirkeci , Belma Taşel %T Rivaroxaban-induced acute pancreatitis %D 2019 %J The European Research Journal %P -2149-3189 %V 5 %N 3 %R doi: 10.18621/eurj.417972 %U 10.18621/eurj.417972
ISNAD Sirkeci, Özgür , Erkuş Sirkeci, Emel , Taşel, Belma . "Rivaroxaban-induced acute pancreatitis". The European Research Journal 5 / 3 (May 2019): 569-571. https://doi.org/10.18621/eurj.417972